Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy AVEO Pharmaceuticals stock in Canada | $7.3

Own AVEO Pharmaceuticals shares in just a few minutes.

AVEO Pharmaceuticals, Inc
-$0.10 (-1.90%)

AVEO Pharmaceuticals is a biotechnology business based in the US. AVEO Pharmaceuticals stocks (AVEO.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $6.3 – an increase of 7.67% over the previous week. AVEO Pharmaceuticals employs 49 staff and has a trailing 12-month revenue of around $7.2 million.

How to buy AVEO Pharmaceuticals stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: AVEO in this case.
  5. Research AVEO Pharmaceuticals stocks. The platform should provide the latest information available.
  6. Buy your AVEO Pharmaceuticals stocks. It's that simple.

How has Coronavirus impacted AVEO Pharmaceuticals's stock price?

Since the stock market crash in March caused by coronavirus, AVEO Pharmaceuticals's stock price has had significant positive movement.

Its last market close was $7.3, which is 27.12% up on its pre-crash value of $5.32 and 1,408.26% up on the lowest point reached during the March crash when the stocks fell as low as $0.484.

If you had bought $1,000 worth of AVEO Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $5,117.20 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $14,257.85.

AVEO Pharmaceuticals stock price

Use our graph to track the performance of AVEO stocks over time.

AVEO Pharmaceuticals stocks at a glance

Information last updated 2021-07-23.
Latest market close$7.3
52-week range$4.13 - $13.21
50-day moving average $6.4606
200-day moving average $7.5426
Wall St. target price$22
Dividend yield N/A (0%)
Earnings per share (TTM) $0.028

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available asset types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0 (if monthly commissions are greater than or equal to US$10.00)
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Is it a good time to buy AVEO Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

AVEO Pharmaceuticals price performance over time

Historical closes compared with the last close of $7.3

1 month (2021-06-25) 4.29%
3 months (2021-04-26) 2.38%

AVEO Pharmaceuticals financials

Revenue TTM USD$7.2 million
Gross profit TTM USD$-16,660,000
Return on assets TTM -35.6%
Return on equity TTM -124.16%
Profit margin 0%
Book value $2.108
Market capitalisation USD$181.1 million

TTM: trailing 12 months

How to short and sell AVEO Pharmaceuticals stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "AVEO.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 1.9 million AVEO Pharmaceuticals stocks held short by investors – that's known as AVEO Pharmaceuticals's "short interest". This figure is 21.6% down from 2.4 million last month.

There are a few different ways that this level of interest in shorting AVEO Pharmaceuticals stocks can be evaluated.

AVEO Pharmaceuticals's "short interest ratio" (SIR)

AVEO Pharmaceuticals's "short interest ratio" (SIR) is the quantity of AVEO Pharmaceuticals stocks currently shorted divided by the average quantity of AVEO Pharmaceuticals stocks traded daily (recently around 565157.14285714). AVEO Pharmaceuticals's SIR currently stands at 3.36. In other words for every 100,000 AVEO Pharmaceuticals stocks traded daily on the market, roughly 3360 stocks are currently held short.

However AVEO Pharmaceuticals's short interest can also be evaluated against the total number of AVEO Pharmaceuticals stocks, or, against the total number of tradable AVEO Pharmaceuticals stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AVEO Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding stocks (for every 100,000 AVEO Pharmaceuticals stocks in existence, roughly 60 stocks are currently held short) or 0.0626% of the tradable stocks (for every 100,000 tradable AVEO Pharmaceuticals stocks, roughly 63 stocks are currently held short).

Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against AVEO Pharmaceuticals.

Find out more about how you can short AVEO Pharmaceuticals stock.

AVEO Pharmaceuticals stock dividends

We're not expecting AVEO Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Have AVEO Pharmaceuticals stocks ever split?

AVEO Pharmaceuticals stocks were split on a 1:10 basis on 20 February 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your AVEO Pharmaceuticals stocks – just the quantity. However, indirectly, the new 900% higher stock price could have impacted the market appetite for AVEO Pharmaceuticals stocks which in turn could have impacted AVEO Pharmaceuticals's stock price.

AVEO Pharmaceuticals stock price volatility

Over the last 12 months, AVEO Pharmaceuticals's stocks have ranged in value from as little as $4.13 up to $13.21. A popular way to gauge a stock's volatility is its "beta".

AVEO.US volatility(beta: 1.2)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while AVEO Pharmaceuticals's is 1.2035. This would suggest that AVEO Pharmaceuticals's stocks are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

AVEO Pharmaceuticals overview

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; AstraZeneca PLC; and Bristol Myers Squibb. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.

Stocks similar to AVEO Pharmaceuticals

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site